Amgen Inc. (ETR:AMG)
Germany · Delayed Price · Currency is EUR | Market Cap | 134.37B |
| Revenue (ttm) | 29.73B |
| Net Income (ttm) | 5.64B |
| Shares Out | n/a |
| EPS (ttm) | 10.41 |
| PE Ratio | 23.84 |
| Forward PE | 14.24 |
| Dividend | 8.59 (3.38%) |
| Ex-Dividend Date | Aug 22, 2025 |
| Volume | 118 |
| Average Volume | 906 |
| Open | 255.45 |
| Previous Close | 255.45 |
| Day's Range | 253.75 - 255.85 |
| 52-Week Range | 230.00 - 308.50 |
| Beta | 0.48 |
| RSI | 60.70 |
| Earnings Date | Nov 4, 2025 |
About Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.
Financial numbers in USD Financial StatementsNews
Hap Sneddon's Top Picks: Amgen, Algonquin Power & iShares Dow Jones US Insurance Index Fund ETF
Hap Sneddon, founder & chief portfolio manager at Castlemoore, shares his top stock picks to watch in the market.
Healthy Returns: Amgen joins a growing list of drugmakers selling directly to consumers
Amgen is the latest drugmaker to sell certain drugs directly to consumers amid pressure from President Donald Trump. Meanwhile, Dr. Oz talks GLP-1s for obesity.
Amgen Unveils New DTC Program, Cuts Cholesterol Drug Price by 60%
AMGN rolls out AmgenNow, a direct-to-consumer program debuting with Repatha at a 60% lower price to boost patient access and affordability.
Amgen (AMGN) Shares Fall Following Discounted Drug Pricing Announcement
Amgen (AMGN) Shares Fall Following Discounted Drug Pricing Announcement
Amgen To Offer Cholesterol Drug At 60% Discount As Trump Administration's Call To Lower Drug Prices
Amgen Inc. (NASDAQ: AMGN) on Monday launched AmgenNow , a new direct-to-patient program starting with Repatha (evolucumab) . AMGN stock is trending lower. View the charts here. This follows results d...
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...
Amgen (AMGN) Reduces Price for Cholesterol Drug Repatha
Amgen (AMGN) Reduces Price for Cholesterol Drug Repatha
Amgen to offer Repatha at 60% discount to U.S. consumers
Amgen cuts Repatha's U.S. price by 60%, making cholesterol treatment more affordable. Read more here.
Amgen Lowers Cholesterol-Medication Price After Trump Call for Price Cuts
The biotechnology company said that it has launched AmgenNow, a new direct-to-patient program, starting with its drug Repatha.
Amgen Slashes Drug Price After Trump Threat--Repatha Now 60% Cheaper Online
Amgen Slashes Drug Price After Trump Threat--Repatha Now 60% Cheaper Online
Amgen (AMGN) Launches AmgenNow with Affordable Pricing for Repatha
Amgen (AMGN) Launches AmgenNow with Affordable Pricing for Repatha
Here's Why Amgen (AMGN) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Amgen to sell cholesterol drug at 60% discount direct to US consumers
LOS ANGELES (Reuters) -Amgen on Monday launched direct-to-consumer U.S. sales of its cholesterol medication Repatha at a discounted cash price, becoming the latest pharmaceutical company responding to...
Amgen to sell cholesterol drug at 60% discount direct to US consumers
Amgen on Monday launched direct-to-consumer U.S. sales of its cholesterol medication Repatha at a discounted cash price, becoming the latest pharmaceutical company responding to U.S. political pressur...
AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S.
Eligible Patients Can Access Repatha at Nearly 60% Discount From the List Price THOUSAND OAKS, Calif. , Oct. 6, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new...
October Dogs Of The Dow Flash One Ideal 'Safer' Dividend Buy
Verizon stands out as the only Dow stock meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its share price. Analyst forecasts suggest top-ten Dow Dogs could deliver average net...
AMGN Quantitative Stock Analysis
Below is Validea's guru fundamental report for AMGEN INC (AMGN). Of the 22 guru strategies we follow, AMGN rates highest using our Shareholder Yield Investor model based on the published strategy of M...
4 Reasons to Buy Amgen Stock Right Now
Key PointsAmgen's weight management candidate looks very promising.
P/E Ratio Insights for Amgen
Looking into the current session, Amgen Inc. (NASDAQ: AMGN) shares are trading at $299.82, after a 0.82% increase. Moreover, over the past month, the stock went up by 5.71% , but in the past year, fe...
XLV, ABT, TMO, AMGN: Large Inflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have de...
Cramer's Stop Trading: Amgen
Jim Cramer breaks down why he's keeping an eye on shares of Amgen.
Cramer's Stop Trading: Amgen
Jim Cramer breaks down why he's keeping an eye on shares of Amgen.
Amgen (AMGN) Hits Key Milestones with Repatha in Cardiovascular Trial
Amgen (AMGN) Hits Key Milestones with Repatha in Cardiovascular Trial
Amgen's Repatha Achieves Key Milestones in Phase 3 Cardiovascular Trial
Amgen's Repatha Achieves Key Milestones in Phase 3 Cardiovascular Trial